These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27399922)

  • 1. EZH2 Protein Expression and Tumor Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Neusquen LP; Filassi JR; Fristachi CE; Carvalho KC; Dória MT; Soares Júnior JM; Piato JR
    Rev Bras Ginecol Obstet; 2016 Jun; 38(6):280-6. PubMed ID: 27399922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship between Expression of Runt-related Transcription Factor 3 and Enhancer of zeste Homolog 2 Proteins and Sensitivity to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer].
    Yuan ZL; Wu XL; Qu M; Xue J; Han L; Sun GY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Dec; 43(6):856-864. PubMed ID: 34980322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
    Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
    Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
    Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Yamanaka A; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
    BMC Cancer; 2017 Feb; 17(1):160. PubMed ID: 28241804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(2):366-71. PubMed ID: 23818347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer.
    Reijm EA; Timmermans AM; Look MP; Meijer-van Gelder ME; Stobbe CK; van Deurzen CHM; Martens JWM; Sleijfer S; Foekens JA; Berns PMJJ; Jansen MPHM
    Ann Oncol; 2014 Nov; 25(11):2185-2190. PubMed ID: 25193989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer.
    Alamgeer M; Ganju V; Kumar B; Fox J; Hart S; White M; Harris M; Stuckey J; Prodanovic Z; Schneider-Kolsky ME; Watkins DN
    Breast Cancer Res; 2014 Apr; 16(2):R44. PubMed ID: 24762066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulatory effect of neoadjuvant chemotherapy on the prognosis of patients with breast cancer.
    Trifunovic J; Memisevic N; Nikolin B; Salma S; Dugandzija T; Vidovic V
    J BUON; 2017; 22(2):638-643. PubMed ID: 28730768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 Protein Expression in Estrogen Receptor Positive Invasive Breast Cancer Treated With Neoadjuvant Endocrine Therapy: An Exploratory Study of Association With Tumor Response.
    Gan Y; Lo Y; Makower D; Kleer C; Lu J; Fineberg S
    Appl Immunohistochem Mol Morphol; 2022 Oct; 30(9):614-622. PubMed ID: 36048167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer.
    Ding Y; Ding K; Qian H; Yu X; Zou D; Yang H; Mo W; He X; Zhang F; Qin C; Zheng Y; Ding X
    PLoS One; 2020; 15(4):e0231895. PubMed ID: 32298374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
    Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
    Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations of
    Ma SJ; Liu YM; Zhang YL; Chen MW; Cao W
    Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29089464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in neoadjuvant chemotherapy versus surgery-first in stage I HER2-positive breast cancer patients in the National Cancer DataBase (NCDB).
    Zeidman M; Schmidt H; Alberty-Oller JJ; Pisapati KV; Ahn S; Mazumdar M; Ru M; Moshier E; Port E
    Breast Cancer Res Treat; 2021 May; 187(1):177-185. PubMed ID: 33392839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of estrogen receptor is associated with worse oncologic outcome in patients who were received neoadjuvant chemotherapy for breast cancer.
    Park YR; Lee J; Jung JH; Kim WW; Park CS; Lee RK; Chae YS; Lee SJ; Park JY; Park JY; Park HY
    Asian J Surg; 2020 Mar; 43(3):467-475. PubMed ID: 31204155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
    Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.